NCT06060145

Brief Summary

This is a randomized controlled human exposure crossover study, aims to explore the health benefits of indoor plants on cardiopulmonary system on adults.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 23, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 29, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

December 21, 2023

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 29, 2024

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2024

Completed
Last Updated

July 25, 2024

Status Verified

July 1, 2024

Enrollment Period

3 months

First QC Date

September 23, 2023

Last Update Submit

July 24, 2024

Conditions

Cardiopulmonary

Outcome Measures

Primary Outcomes (1)

  • Forced Vital Capacity(FVC)

    We plan to measure forced vital capacity (FVC) of lung function.

    Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

Secondary Outcomes (2)

  • Blood Pressure(BP)

    Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

  • Heart Rate Variability(HRV)

    Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

Other Outcomes (3)

  • C-reactive protein(CRP)

    Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

  • Interleukin-6(IL-6)

    Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

  • Tumor necrosis factor-α(TNF-α)

    Time Frame: Baseline and after 4 weeks plants exposure in first stage, and after washout period, baseline and after 4 weeks plants exposure in second stage.

Study Arms (2)

Plants placed in an office environment

EXPERIMENTAL

Participants in this group will receive an intervention of plants placed in an office environment.

Other: Plants placed in an office environment

Devoid of any plant presence in an office environment

ACTIVE COMPARATOR

Participants in this group will be exposed to an office environment devoid of any plant presence.

Other: Devoid of any plant presence in an office environment

Interventions

Plants placed in an office environmentOTHER

The intervention group will be provided with an intervention consisting of 34-38 potted plants arranged in an office environment for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.

Plants placed in an office environment
Devoid of any plant presence in an office environmentOTHER

Participants assigned to the control group will be exposed to an office environment devoid of any plant presence for a duration of 8 hours (09:00-17:00) on weekdays (Monday to Friday) for 4 weeks.

Devoid of any plant presence in an office environment

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Living in Hangzhou during the study period;
  • Non-smoking, no history of alcohol or drug abuse;
  • Staying indoors in daytime we required.

You may not qualify if:

  • Current or ever smokers;
  • Subjects with allergic disease, such as allergic rhinitis, allergic asthma, and atopy;
  • Subjects with cardiovascular disease, such as congenital heart disease, pulmonary heart disease, and hypertension;
  • Subjects with respiratory disease, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease;
  • Subjects with chronic disease, such as diabetes, chronic hepatitis, and kidney disease;
  • Subjects with a history of major surgery;
  • Medication use or dietary supplements intake in recent two months;
  • Unable to cooperate with follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhejiang Chinese Medicine University

Huangzhou, Zhejiang, 310000, China

Location

Study Officials

  • Lina Zhang, Ph.D

    School of Public Health, Zhejiang Chinese Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

September 23, 2023

First Posted

September 29, 2023

Study Start

December 21, 2023

Primary Completion

March 29, 2024

Study Completion

March 31, 2024

Last Updated

July 25, 2024

Record last verified: 2024-07

Locations

CN(1)